Pfizer posted growth in its biopharma division, but overall sales fell amid increased competition in its generic-drug business
As the coronavirus continues to spread around the globe, companies and academic labs are racing to develop a vaccine that would help society get back to normal. But there could also be costs to moving too quickly.
WSJ’s Daniela Hernandez explains. Photo illustration: Laura Kammermann日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Hasbro revenue falls 29% as store closures, product shortages hurt sales; shares fallStore closures, product shortages and lower retail inventory hampered Hasbro in the second quarter, as the company posted weaker-than-expected earnings on Monday.
続きを読む »
Stocks making the biggest moves after hours: Pfizer, F5 Networks, Virgin Galactic and moreSee which stocks are posting big moves after the bell.
続きを読む »
Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday
続きを読む »
Moderna, Pfizer Coronavirus Vaccines Begin Final-Stage TestingTwo of the most advanced experimental vaccines entered the pivotal phase of their studies, with the first subjects receiving doses of Moderna vaccine and Pfizer preparing to inject participants in its trial.
続きを読む »
Pfizer, BioNTech could submit vaccine for approval by Oct – latest updatesPfizer, BioNTech could submit vaccine for approval by October. Other Covid19 updates: 🌍 Virus-linked hunger tied to 10,000 child deaths a month 🇧🇴 Bolivian prisoners riot over virus exposure 🇰🇪 Kenya extends lockdown by 30 days More here:
続きを読む »
Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidateGerman biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
続きを読む »